Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Internal and Emergency Medicine
Published in: Internal and Emergency Medicine 5/2018

01-08-2018 | CE - LETTER TO THE EDITOR

Aristolochia, a nephrotoxic herb, still surfs on the Web, 15 years later

Authors: Valentina Maggini, Francesca Menniti-Ippolito, Fabio Firenzuoli

Published in: Internal and Emergency Medicine | Issue 5/2018

Login to get access

Excerpt

Plants in the family Aristolochiaceae contain aristolochic acid, recognized worldwide as cause of serious nephropathy and cancer [1, 2]. In 2001, the Food and Drug Administration (FDA) issued warnings and an important alert on the risks associated with herbal products containing aristolochic acid [3]. In 2002, The International Agency classified products containing Aristolochia species as human carcinogens for Research on Cancer [3]. Despite this, in 2003 Gold and Slone highlighted the sale on the Web of many products containing aristolochic acid [3]. …
Literature
1.
Jadot I, Declèves AE, Nortier J, Caron N (2017) An integrated view of aristolochic acid nephropathy: update of the literature. Int J MolSci 18(2):e297CrossRef
2.
Grollman AP, Marcus DM (2016) Global hazards of herbal remedies: lessons from Aristolochia: the lesson from the health hazards of Aristolochia should lead to more research into the safety and efficacy of medicinal plants. EMBO Rep 17(5):619–625CrossRefPubMedPubMedCentral
3.
Gold LS, Slone TH (2003) Aristolochic acid, an herbal carcinogen, sold on the Web after FDA alert. N Engl J Med 349(16):1576–1577CrossRefPubMed
4.
Cousyn G, Dalfrà S, Scarpa B (2013) Project BELFRIT. Eur Food Feed Law Rev 8(3):3187–3196
5.
Maggini V, Gallo E, Vannacci A, Gori L, Mugelli A, Firenzuoli F (2013) e-Phytovigilance for misleading herbal information. Trends Pharmacol Sci 34(11):594–595CrossRefPubMed
Metadata
Title
Aristolochia, a nephrotoxic herb, still surfs on the Web, 15 years later
Authors
Valentina Maggini
Francesca Menniti-Ippolito
Fabio Firenzuoli
Publication date
01-08-2018
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 5/2018
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-018-1813-2

Other articles of this Issue 5/2018

Internal and Emergency Medicine 5/2018 Go to the issue

Author Correction

Author Correction: Toxic alcohol diagnosis and management: an emergency medicine review

POINT OF VIEW

Daylight saving time, circadian rhythms, and cardiovascular health

IM - ORIGINAL

Risk, prevalence, and impact of hospital malnutrition in a Tertiary Care Referral University Hospital: a cross-sectional study

IM - COMMENTARY

Oxidative stress and inflammation: new molecular targets for cardiovascular diseases

EM - ORIGINAL

Early postictal serum lactate concentrations are superior to serum creatine kinase concentrations in distinguishing generalized tonic–clonic seizures from syncopes

EM - ORIGINAL

Myocardial dysfunction after out-of-hospital cardiac arrest: predictors and prognostic implications
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits